We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
We kick off a new week of trading with continued optimism regarding U.S.-China trade talks. Yesterday, President Trump announced he will again postpone the tariff hike on Chinese goods coming into the U.S. from 10% to 25%. After citing “very productive talks” with Chinese President Xi Jinping, Trump hopes to conclude a new trade deal at his “Winter White House” in Mar-a-Lago, Florida at an unspecified time in the near future.
Overnight, the Shanghai Composite rose 5.6% on this news, with the Shenzhen index up 5.4%. This has brought U.S. index futures up into the green in today’s pre-market, with the Dow +150 points, the Nasdaq +54 and the S&P 500 +14.5 at this hour. The S&P is looking to cross back over 2800 for the first time since early November of last year, and is currently +11.4% year to date as of Friday’s close. The Dow is +11.5% since 2019 began and the Nasdaq is +12.9% over the same time frame.
GE Sells Biopharma Unit for $21.4 Billion
General Electric (GE - Free Report) has sold its biopharmaceutical unit to Danaher (DHR - Free Report) for $21.4 billion, in a move that will help the giant conglomerate continue to pay down debt. The move, led by GE CEO Larry Culp — who used to be CEO of Danaher — comes as something of a surprise; earlier expectations was for an IPO spin-off of GE’s biopharma wing along with its entire healthcare unit. Traders appear to like this deal very much: not only are GE shares up 14% following the announcement, but Danaher has gained over 5% in today’s pre-market as well.
Late last year, GE’s share price slipped all the way to $7 per share, to their lowest depths in more than 25 years. Since then, perceptions of the company’s board taking responsibility to address difficult changes — first with CEO John Flannery and Culp as of 4 months ago — have improved the company’s situation greatly. Based on where this news has brought shares in today’s pre-market, GE stock is up near 45% year to date. GE shares currently carry a Zacks Rank #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Positive Development on Trade War Front
We kick off a new week of trading with continued optimism regarding U.S.-China trade talks. Yesterday, President Trump announced he will again postpone the tariff hike on Chinese goods coming into the U.S. from 10% to 25%. After citing “very productive talks” with Chinese President Xi Jinping, Trump hopes to conclude a new trade deal at his “Winter White House” in Mar-a-Lago, Florida at an unspecified time in the near future.
Overnight, the Shanghai Composite rose 5.6% on this news, with the Shenzhen index up 5.4%. This has brought U.S. index futures up into the green in today’s pre-market, with the Dow +150 points, the Nasdaq +54 and the S&P 500 +14.5 at this hour. The S&P is looking to cross back over 2800 for the first time since early November of last year, and is currently +11.4% year to date as of Friday’s close. The Dow is +11.5% since 2019 began and the Nasdaq is +12.9% over the same time frame.
GE Sells Biopharma Unit for $21.4 Billion
General Electric (GE - Free Report) has sold its biopharmaceutical unit to Danaher (DHR - Free Report) for $21.4 billion, in a move that will help the giant conglomerate continue to pay down debt. The move, led by GE CEO Larry Culp — who used to be CEO of Danaher — comes as something of a surprise; earlier expectations was for an IPO spin-off of GE’s biopharma wing along with its entire healthcare unit. Traders appear to like this deal very much: not only are GE shares up 14% following the announcement, but Danaher has gained over 5% in today’s pre-market as well.
Late last year, GE’s share price slipped all the way to $7 per share, to their lowest depths in more than 25 years. Since then, perceptions of the company’s board taking responsibility to address difficult changes — first with CEO John Flannery and Culp as of 4 months ago — have improved the company’s situation greatly. Based on where this news has brought shares in today’s pre-market, GE stock is up near 45% year to date. GE shares currently carry a Zacks Rank #3 (Hold).